arrow_back Back Filing freshness 10-Q Q3 FY2026 SEC EDGAR

GLAUKOS Corp

GKOS
$220.01 ▼ -26.47 (-10.74%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
53 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
18
Health
Poor
Bearish
auto_awesome

Analytical Summary

GLAUKOS Corp faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $13.0B
Dividend Yield —
Revenue Growth 58.0% ↗
Op. Margin 0.4% ↗
ROIC 0.1% ↗
FCF / Share $0.62 ↗
Trailing P/E 7333.7x
Price / Book 18.2x
FCF Yield 0.3%
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

53-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$211.03M
↑ +58.0% —
Net Income Profit after all expenses
$2.02M
↑ +111.0% —
Operating Margin Operating profit as % of sales
0.4%
↑ +104.2% 6th
FCF / Share Free cash flow per share
$0.62
↑ +200.5% —
Long-Term Debt Long-term obligations
$3.04M
↓ -42.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
10
Returns ↓
24
Financial Health ↓
18
Cash Quality ↓
26

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 14 years · 53 quarters